WO 2005/040795 PCT/EP2004/011007

SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with Aminopeptidase-Like 1 (NPEPL1)

<130> BHC 03 01 006

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 1691

<212> DNA

<213> Homo sapiens

<400> 1

gggccgggca gggccggggc gtgggccggc aggaagatgg cgaacgtggg gctgcagttc 60 caggegageg egggggaete ggaeceacag ageeggeeee tgetgetget egggeagetg 120 caccacctgc accgcgtgcc ctggagccac gtccgcggga agctgcagcc ccgggtcacc 180 gaggagetet ggeaggetge cetgageaeg etcaacecea acceeaegga cagetgteee 240 etetacetaa etacgecace gtggetgeee tgeeetgeag ggtgageegg cacaacagee 300 360 cctcggccgc ccacttcatc acgcggctgg tgcggacctg cctgccgccc ggagcgcatc getgeattgt gatggtetge gageageeag aggtetttge tteegeetgt geeetggeee 420 480 gggcettece getgtteace cacegeteag gtgceteteg gegettggag aagaagaegg 540 tcaccgtgga gtttttcctg gtgggacaag acaacgggcc ggtggaggtg tccacattgc agtgettage gaatgecaca gaeggegtge ggetageage cegeategtg gaeacaceet 600 gcaatgagat gaacaccgac accttcctcg aggagattaa caaagctgga aaggagctgg 660 ggatcatccc aaccatcatc cgggatgagg aactgaagac gagaggattt ggaggaatct 720 780 atggggttgg caaagccgcc ctgcatcccc cagccctggc cgtcctcagc cacaccccag atggagccac gcagaccatc gcctgggtgg gcaaaggcat cgtctatgac actggaggcc 840 900 tcagcatcaa agggaagact accatgccgg ggatgaagcg agactgcggg ggtgctgcgg ccgtcctggg ggccttcaga gccgcaatca agcagggttt caaagacaac ctccacgctg 960 1020 tgttctgctt ggctgagaac tcggtggggc ccaatgcgac agggccagat gacatccacc tgctgtactc agggaagacg gtggaaatca acaacacgga tgccgagggc aggctggtgc 1080 1140 tggcagatgg cgtgtcctat gcttgcaagg acctgggggc cgacatcatc ctggacatgg ccaccetgae eggggeteag ggeattgeea cagggaagta ccaegeegeg gtgeteacea 1200 1260 acagegetga gtgggaggee geetgtgtga aggegggeag gaagtgtggg gaeetggtge accegetggt ctactgeece gagetgeact teagegagtt caceteaget gtggeggaca 1320 1380 tgaagaactc agtggcggac cgagacaaca gccccagctc ctgtgctggc ctcttcatcg cctcacacat cggcttcgac tggcccggag tctgggtcca cctggacatt gctgcaccgg 1440 tgcatgctgg tgagcgagcc acaggcttcg gtgtggccct cctgctggcg ctcttcggcc 1500 gtgcctctga ggaccctctg ctgaacctgg tgtccccact gggctgtgag gtggatgtcg 1560

1620 1680 1691

aggaggggga cetggggagg gactecaaga gacgcagget tgtgtgagee teetgeeteg												
gccctgacaa acggggatct tttacctcac tttgcactga ttaattttaa gcaattgaaa												
gattgccctt c												
· ,												
<210> 2												
<211> 411												
<212> PRT												
<213> Homo sapiens												
<400> 2												
Met Val Cys Glu Gln Pro Glu Val Phe Ala Ser Ala Cys Ala Leu Ala												
1 5 10 15												
Arg Ala Phe Pro Leu Phe Thr His Arg Ser Gly Ala Ser Arg Arg Leu												
20 25 30												
Glu Lys Lys Thr Val Thr Val Glu Phe Phe Leu Val Gly Gln Asp Asn												
35 40 45												
Gly Pro Val Glu Val Ser Thr Leu Gln Cys Leu Ala Asn Ala Thr Asp												
50 55 60												
Gly Val Arg Leu Ala Ala Arg Ile Val Asp Thr Pro Cys Asn Glu Met												
65 70 75 80												
Asn Thr Asp Thr Phe Leu Glu Glu Ile Asn Lys Val Gly Lys Glu Leu												
85 90 95												
Gly Ile Ile Pro Thr Ile Ile Arg Asp Glu Glu Leu Lys Thr Arg Gly												
100 105 110												
Phe Gly Gly Ile Tyr Gly Val Gly Lys Ala Ala Leu His Pro Pro Ala												
115 120 125												
Leu Ala Val Leu Ser His Thr Pro Asp Gly Ala Thr Gln Thr Ile Ala												
130 135 140												
Trp Val Gly Lys Gly Ile Val Tyr Asp Thr Gly Gly Leu Ser Ile Lys												
145 150 155 160												
Gly Lys Thr Thr Met Pro Gly Met Lys Arg Asp Cys Gly Gly Ala Ala												
165 170 175												
Ala Val Leu Gly Ala Phe Arg Ala Ala Ile Lys Gln Gly Phe Lys Asp												
180 185 190												
Asn Leu His Ala Val Phe Cys Leu Ala Glu Asn Ser Val Gly Pro Asn												
195 200 205												
Ala Thr Arg Pro Asp Asp Ile His Leu Leu Tyr Ser Gly Lys Thr Val												
210 215 220												
Glu Ile Asn Asn Thr Asp Ala Glu Gly Arg Leu Val Leu Ala Asp Gly												
225 230 235 240												
Val Ser Tyr Ala Cys Lys Asp Leu Gly Ala Asp Ile Ile Leu Asp Met												
245 250 255												
Ala Thr Leu Thr Gly Ala Gln Gly Ile Ala Thr Gly Lys Tyr His Ala												
260 265 270												
200 200 2.0												

PCT/EP2004/011007

21

cattegetaa geactgeaat g

	Ala Va	l Leu	Thr	Asn	Ser	Ala	Glu	Trp	Glu	Ala	Ala	Cys	Val	Lys	Ala		
		275					280					285					
	Gly A	g Lys	Cys	Gly	Asp	Leu	Val	His	Pro	Leu	Val	Tyr	Cys	Pro	Glu		
	. 29	0				295					300						
	Leu Hi	s Phe	Ser	Glu	Phe	Thr	Ser	Ala	Val	Ala	Asp	Met	Lys	Asn	Ser	•	
	305				310					315					320		
	Val Al	a Asp	Arg	Asp	Asn	Ser	Pro	Ser	Ser	Cys	Ala	Gly	Leu	Phe	Ile		
	•			325					330					335			
	Ala Se	r His	Ile	Gly	Phe	Asp	Trp	Pro	Gly	Val	Trp	Val	His	Leu	Asp		
			340					345					350				
	Ile Al	a Ala	Pro	Val	His	Ala	Gly	Glu	Arg	Ala	Thr	Gly	Phe	Gly	Val		
		355					360					365					
	Ala Le	u Leu	Leu	Ala	Leu	Phe	Gly	Arg	Ala	Ser	Glu	Asp	Pro	Leu	Leu		
	37					375					380						
	Asn Le	u Val	Ser	Pro	Leu	Gly	Cys	Glu	Val	Asp	Val	Glu	Glu	Gly			
	385				390					395	-			-	400		
	Leu Gl	y Arg	Asp		Lys	Arg	Arg	Arg		Val							
				405					410								
				•													
	<210>																
	<211>	21															
	<212>	DNA		_	-	•											
<213> artificial sequence																	
	-000																
	<220>	£a			~~												
<223> forward primer																	
	-400>	3															
<400> 3														21			
ttttcctggt gggacaagac a																	
	<210>	4															
	<211>			•													
	<212>																
	<213>			al s	egue	nce											
					_												
	<220×			•													
	<223>	reve	rse j	prime	er										•		
	<400>	4															

WO 2005/040795 PCT/EP2004/011007

-4-

<210> 5
<211> 18
<212> DNA
<213> artificial sequence
<220>
<223> probe

cgggccggtg gaggtgtc

<400> 5

18